These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38918657)
1. Anti-Leukemic Effects of Small Molecule Inhibitor of c-Myc (10058-F4) on Chronic Myeloid Leukemia Cells. Zehtabcheh S; Sheikh-Zeineddini N; Yousefi AM; Bashash D Asian Pac J Cancer Prev; 2024 Jun; 25(6):1959-1967. PubMed ID: 38918657 [TBL] [Abstract][Full Text] [Related]
2. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. Wei YL; Liang Y; Xu L; Zhao XY Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306 [TBL] [Abstract][Full Text] [Related]
3. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes. Farhadi E; Zaker F; Safa M; Rezvani MR Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565 [TBL] [Abstract][Full Text] [Related]
4. Anti-Cancer Role of Dendrosomal Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K/AKT/mTOR Signaling Pathway and Inhibition of hTERT Expression. Asgaritarghi G; Farsani SSM; Sadeghizadeh D; Najafi F; Sadeghizadeh M Curr Mol Pharmacol; 2023 Mar; 16(5):592-608. PubMed ID: 35578888 [TBL] [Abstract][Full Text] [Related]
5. C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells. Zehtabcheh S; Yousefi AM; Momeny M; Bashash D Mol Biol Rep; 2023 Dec; 50(12):10157-10167. PubMed ID: 37924446 [TBL] [Abstract][Full Text] [Related]
6. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Dai Y; Rahmani M; Pei XY; Dent P; Grant S Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284 [TBL] [Abstract][Full Text] [Related]
7. Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling. Hao G; Zhai J; Jiang H; Zhang Y; Wu M; Qiu Y; Fan C; Yu L; Bai S; Sun L; Yang Z Biomed Pharmacother; 2020 Feb; 122():109677. PubMed ID: 31810012 [TBL] [Abstract][Full Text] [Related]
8. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity. Zehtabcheh S; Yousefi AM; Salari S; Safa M; Momeny M; Ghaffari SH; Bashash D Cell Biol Int; 2021 May; 45(5):1111-1121. PubMed ID: 33501756 [TBL] [Abstract][Full Text] [Related]
9. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation. Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431 [TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773 [TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973 [TBL] [Abstract][Full Text] [Related]
12. Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation. Lee J; Zhang G; Wu X; Xu F; Zhou J; Zhang X J Cancer Res Clin Oncol; 2012 Dec; 138(12):2095-102. PubMed ID: 22833150 [TBL] [Abstract][Full Text] [Related]
13. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus. Wang J; Huang T; Sun J; Yu Y; Liu Z; Li W; Jia J; Chen C Med Oncol; 2014 Aug; 31(8):112. PubMed ID: 25023053 [TBL] [Abstract][Full Text] [Related]
14. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro]. Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538 [TBL] [Abstract][Full Text] [Related]
15. Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells. Al-Rawashde FA; Wan Taib WR; Ismail I; Johan MF; Al-Wajeeh AS; Al-Jamal HAN Asian Pac J Cancer Prev; 2021 Dec; 22(12):3959-3965. PubMed ID: 34967577 [TBL] [Abstract][Full Text] [Related]
16. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment. Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838 [TBL] [Abstract][Full Text] [Related]
17. Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells. Engür S; Dikmen M; Öztürk Y Immunopharmacol Immunotoxicol; 2016; 38(2):87-97. PubMed ID: 26667773 [TBL] [Abstract][Full Text] [Related]
18. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012 [TBL] [Abstract][Full Text] [Related]
19. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia. Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244 [TBL] [Abstract][Full Text] [Related]
20. Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis. Liu N; Li P; Zang S; Liu Q; Ma D; Sun X; Ji C PLoS One; 2015; 10(2):e0116880. PubMed ID: 25647305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]